POIETIS
MAKES TISSUES REAL
3D Bioprinting innovation
Shaping tomorrow’s therapies
A strong interdisciplinary team to be at the top of innovation
Founded in 2014 as a spin-off from INSERM and the University of Bordeaux, Poietis’ mission is to provide innovative solutions leveraging its proprietary next-generation bioprinting (NGB) platform and bring tissue engineering therapies to patients.
As an innovative company, Poietis filed over 100 exclusive patents !
Poietis gathers a strong and interdisciplinary team of biologists, physicists, AI specialists, developers with extremely rich and diverse expertise. Together, we thrive to develop what is the most advanced bioprinting platform to date and use it to create tissues for key applications such as regenerative medicine and in-vitro testing.
Poietis’ strong core values: shaping the future of biomedical innovation
At Poietis, we are inspired by a vision to revolutionize healthcare. Our core values are the heartbeat of our mission, driving us to pioneer innovative and ethical solutions in regenerative medicine, while fostering a culture of learning, collaboration, and excellence.
Innovation and Pioneering in Medicine
Poietis is dedicated to innovation in regenerative medicine, developing new technologies and therapeutic solutions with the ambition to be a pioneer in the field.
Growth Through Learning
Poietis values continuous learning, encouraging its teams to develop their sense of responsibility and autonomy for consistent professional advancement.
Humanism and Social Responsibility
Poietis commits to facilitating research and development in medical biotechnology, aiming to create treatments with lasting and positive human impacts, while respecting ethical principles.
Openness and Collaboration
Management and staff foster an environment that promotes exchange and solidarity, both within and across teams, and with partners, to align with their expectations and needs.
Rigorous Work Ethic
Poietis adheres to a high standard of requirements in line with health industry standards, encompassing regulatory aspects and quality management across all research, development, and production activities.
Poietis’ Management team, a trio of experts
Fabien Guillemot, PhD
Co-founder, President and CSO
Fabien is an entrepreneur with over two decades of experience in Regenerative Medicine, holding a PhD in Material Science and an Habilitation in Health and Life Sciences.
Ex-Researcher at INSERM, Invited Researcher at Harvard, he is a recognized pioneer in bioprinting.
Fabien has also enhanced his scientific expertise with entrepreneurial training from HEC Paris.
Bruno Buisson
Co-founder, General Manager and CBO
With a 30-year trajectory in biotech, Bruno has worked in the US and France, transitioning from Research Associate and Analyst in biochemistry to executive roles (Cellectis, Mauna Kea Technologies, Fluofarma, Biospace Lab) and consultancy. He founded BLS Consulting to drive business development in various health-related industries and co-founded Poietis in 2014.
Bertrand Viellerobe, PhD
CTO
Bertrand brings +20 years of photonics expertise, with a Ph.D. in Physics focused on single-molecule detection. Former R&D Manager at Mauna Kea Technologies, developing an ultra-miniaturized medical microscope, and directing over 220 photonics projects at Bordeaux’s « Route des Lasers® » cluster. He has 25 publications and co-invented 13 patents.
An imminent SAB accompanies Poietis
Dr. Geoffrey Gurtner, MD
Dr. Gurtner, MD, is a distinguished professor at Stanford University, holding dual roles in Surgery and Materials Science and Engineering, and is the Executive Director of the Stanford Wound Care Center.
With degrees from Dartmouth College and UCSF School of Medicine, and advanced training from Massachusetts General Hospital and NYU, he is a double board-certified surgeon with over 180 publications and editor of two major textbooks. Renowned for his research, he has received prestigious awards in plastic surgery, contributed to the development of innovative biomedical technologies, and co-founded startups in wound healing and cardiovascular health.
Dr. Michael May, PhD
Dr. May, a former NSERC Scholar with a PhD in Chemical Engineering from the University of Toronto, is the CEO of the Center for Commercialization of Regenerative Medicine (CCRM) and CCRM Enterprises. He previously co-founded Rimon Therapeutics, focusing on advanced wound healing. An active member of the biotech community, May serves on multiple boards and committees, including those related to entrepreneurship at the University of Toronto, and is Chair of ExcellThera.
Join the team!
Do you think you have the motivation to join our team and work in a dynamic, innovative company?
Do you want to know more about NGB platform?